Protox has completed non-clinical testing for the development of botulinum toxin (Botox) and is preparing for full-scale phase 1 clinical trials.

DSK subsidiary Protox (CEO Lee Dong-beom) announced on the 21st that it had recently completed non-clinical testing for a botulinum toxin preparation (tentative name Protoxin).

Protox said, “We have secured the results necessary to conduct a phase 1 clinical trial through non-clinical trials,” and “we plan to proceed with a phase 1 clinical trial next year as planned.”

Non-clinical trials of Protox have been conducted at BiotoxTech, a certified GLP institute, and the Safety Evaluation Research Institute since February. No abnormal symptoms were observed during the animal experiment observation period. In particular, in terms of ‘muscle contraction inhibition’ efficacy, it was confirmed that the results were more durable than the control substance at the same or partial dose.

A Protox official explained, “In order to enter phase 1 smoothly, we secured primate safety compared to other companies early by completing monkey toxicity tests,” and added, “We are focusing on producing products that reduce the number of administrations by improving quality and sustainability.”

He added, “Currently, Protox is preparing for GMP inspection to produce clinical samples,” and “We are accelerating preparations for submission of Phase 1 IND in the first half of next year.”

Previously, Protox signed a contract for domestic clinical trials with Promedis Co., Ltd. (CEO Eun-jeong Jeon), a clinical trial trust agency.

Lee Dae-ho, Money Today Broadcasting MTN reporter